-
Worldwide Revenue (Q4 2024): $23.8 million, a 23% increase year-over-year.
-
Full Year 2024 Revenue: $83.8 million, a 22% increase over 2023.
-
US Revenue (Q4 2024): $15.9 million, a 16% increase year-over-year.
-
International Revenue (Q4 2024): $7.9 million, a 42% increase year-over-year.
-
Gross Margin (Q4 2024): 74%, compared to 75% in the prior year period.
-
Total Operating Expenses (Q4 2024): $31 million, a 9% increase year-over-year.
-
Net Loss (Q4 2024): $13.2 million, or $0.33 per share.
-
Adjusted EBITDA Loss (Q4 2024): $7.5 million, a 10% improvement year-over-year.
-
Cash Equivalents and Marketable Securities (End of 2024): $101.5 million.
-
2025 Revenue Guidance: Expected between $96 million and $98 million.
-
2025 Gross Margin Guidance: Approximately 74%.
-
2025 Operating Expenses Guidance: Between $133 million and $135 million.
Release Date: February 19, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
-
Pulmonx Corp (NASDAQ:LUNG) reported a 23% increase in worldwide sales for Q4 2024, reaching $23.8 million, driven by strong US and international sales growth.
-
The company added 52 new centers in the US in 2024, ending the year with 283 active accounts, indicating successful expansion of its US account base.
-
Pulmonx Corp (NASDAQ:LUNG) launched the Lung Tracks platform to streamline customer workflows and identify eligible patients, showing innovation in patient management.
-
The company reported successful clinical trial results, with 77.6% of patients showing successful conversion of collateral ventilation status after treatment.
-
Pulmonx Corp (NASDAQ:LUNG) achieved a 22% growth in full-year 2024 worldwide revenue, reflecting substantial progress in commercial initiatives and market expansion.
-
Despite strong revenue growth, Pulmonx Corp (NASDAQ:LUNG) reported a net loss of $13.2 million for Q4 2024, indicating ongoing financial challenges.
-
The company’s gross margin for Q4 2024 was 74%, slightly down from 75% in the prior year period, suggesting pressure on profitability.
-
Operating expenses increased by 9% in Q4 2024, driven by higher clinical expenses and commercial investments, impacting overall financial performance.
-
Pulmonx Corp (NASDAQ:LUNG) anticipates a negative impact of approximately 100 basis points on 2025 reported revenue due to foreign exchange fluctuations.
-
The company expects 2025 revenue growth to be below its long-term target of 20%, with guidance set at 16-18% constant currency growth, indicating potential challenges in achieving its growth objectives.
